Morningstar

Ipsen SA IPN

Morningstar Rating
Unlock
Stock XPAR Rating as of
€112.60 +0.70 (0.63%)
View Full Chart
As of Delayed Price Open

Company Report

View Archive

Narrow-Moat Ipsen's Growth Platforms and Pipeline Should Help Offset Generic Erosion of Somatuline

Rachel Elfman

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. The company has a global footprint and sells more than 25 drugs in 115 countries, and it has a direct commercial presence in 34 countries. Over the past nearly 100 years, the company has shifted its focus to specialty care products and away from its legacy consumer healthcare segment.

Read Full Report

Price vs Fair Value

View History
IPN is trading at a 80% premium.
Price
€111.90
Fair Value
€278.00
Uncertainty
Medium
1-Star Price
€737.00
5-Star Price
€52.00
Economic Moat
Vmsgbp
Capital Allocation
Nqrjmlvx

Bulls Say, Bears Say

Bulls

Ipsen has a sound financial structure and strong cash generation, which allows it to further develop and expand its pipeline.

Bears

Many of Ipsen’s products are facing competitive pressures from lower-priced generics.

Show More

News

View All

Trading Information

Previous Close Price
€111.90
Day Range
€111.70–112.70
52-Week Range
€99.70–126.70
Bid/Ask
€112.40 / €112.60
Market Cap
€9.31 Bil
Volume/Avg
5,933 / 67,381

Key Statistics

Price/Earnings (Normalized)
12.37
Price/Sales
2.72
Dividend Yield (Trailing)
1.07%
Dividend Yield (Forward)
1.07%
Total Yield
1.07%

Company Profile

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
5,325
Website
https://www.ipsen.com

Competitors

Valuation

View More
Metric
IPN
UCB
EXEL
Price/Earnings (Normalized)
 12.3740.3517.37
Price/Book Value
 2.423.483.57
Price/Sales
 2.725.884.05
Price/Cash Flow
 10.6745.0316.58
Price/Earnings
IPN
UCB
EXEL

Financial Strength

Metric
IPN
UCB
EXEL
Quick Ratio
 0.860.754.05
Current Ratio
 1.171.194.27
Interest Coverage
 21.203.15—
Quick Ratio
IPN
UCB
EXEL

Profitability

Metric
IPN
UCB
EXEL
Return on Assets (Normalized)
 12.69%4.48%14.82%
Return on Equity (Normalized)
 21.64%7.73%19.05%
Return on Invested Capital (Normalized)
 19.82%6.73%14.99%
Return on Assets
IPN
UCB
EXEL

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
WdvtykzngjYpdt$87.2 Bil
 Merck KGaA ADR
MKKGY
LlwnqwdtqtSsmhgjx$75.7 Bil
 Haleon PLC ADR
HLN
GmgwkthxSvk$47.3 Bil
 Teva Pharmaceutical Industries Ltd ADR
TEVA
SpslkwzvjLbxv$20.0 Bil
 Viatris Inc
VTRS
YvrcxglJdjd$13.7 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
NgnlzqznFhnk$13.4 Bil
 Catalent Inc
CTLT
FftbhfhMzpbz$11.0 Bil
 Prestige Consumer Healthcare Inc
PBH
HjzlkwqVpxfby$3.5 Bil
 Perrigo Co PLC
PRGO
TtmwtvqjVpr$3.4 Bil
 Green Thumb Industries Inc
GTBIF
RfwypfblcwVdxz$2.4 Bil

Sponsor Center